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Clinical implications of antimicrobial resistance: how big is 
the problem? 
Georgia Duckworth 
This presentation addresses the question of the size of the antimicrobial resistance problem by examining the 
monitoring of antimicrobial use and resistance. It focuses on the main sources of information, possible pitfalls of the 
data and the susceptibility of the main pathogens responsible for bacteraemias in England and Wales. It addresses 
some of the difficulties in establishing the link between antimicrobial resistance and antimicrobial prescribing and 
concludes with some thoughts on necessary developments. 
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The remit of this paper was to address the size of the 
antimicrobial resistance problem; clearly an impossible 
task. However, by defining some parameters, an attempt 
will be made to address this question with regard to 
potentially life-threatening infections caused by common 
bacterial pathogens in England and Wales. 
SURVEILLANCE OF ANTIMICROBIAL USE 
AND RESISTANCE 
Measuring the size of the problem is dependent on 
surveillance activities around antimicrobial resistance. 
This has two facets: surveillance of the prevalence and 
levels of resistance and surveillance of antimicrobial 
use, which might contribute to increasing resistance in 
potential pathogens. These two aspects contribute to 
individual patient care and the wider public health in 
slightly different ways. 
Surveillance of antimicrobial resistance 
The surveillance of antimicrobial resistance allows 
decisions to be made on the appropriate treatment of 
individual patients and, on the wider scale, on the 
development of prescribing policies in the hospital and 
community. In addition to these measures, it monitors 
changing patterns of resistance, in particular signalling 
emerging problems. This allows prevention and control 
measures to be targeted appropriately and subsequently 
evaluated, while areas for further research, especially 
with regard to the development of new antimicrobial 
agents, are identified. 
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Surveillance of antimicrobial use 
Surveillance of antimicrobial use provides insight into 
the other side of the coin, allowing the exploration of the 
relationship between antimicrobial use and anti- 
microbial resistance and interpretation of trends and 
variations in antimicrobial resistance rates. 
Sources of information on antimicrobial resistance 
The main sources of information contributing to 
knowledge on antimicrobial resistance in the England 
and Wales are: 
1. routine laboratory reports to the Communicable 
Disease Surveillance Centre (CDSC) of the Public 
Health Laboratory Service (PHLS); 
2. information on isolates referred to the national 
reference laboratories of the PHLS; 
3. prescribing analyses and cost data from the 
Prescription Pricing Authority; 
4. hospital activity statistics; 
5. information from ad hoc studies or surveys. 
SURVEILLANCE: BIASES AND CAVEATS 
Whenever surveillance data is being examined and 
interpreted, it is important to recognize that there are 
usually many caveats. Variations in practice account for 
inherent biases in antimicrobial resistance rates; for 
instance, a general practitioner consultation does not 
necessarily reflect the severity of a patient’s illness 
but is more closely allied to their normal behaviour in 
consulting their doctor. Whether this consultation then 
results in a specimen being taken is also dependent on 
a variety of factors: mid-stream urine specimens are not 
only taken for suspected urinary tract infections, but 
also when patients present with many other different 
problems, such as backache. The inverse of this is that 
about 50% of prescribing in the community is related to 
respiratory tract infections, but sputum specimens are 
rarely sent for microbiological investigation in these 
circumstances. Specimens sent to the laboratory may 
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Figure 1. Ampicillin resistance in Escherichia co/i from blood 
and cerebrospinal fluid samples in England and Wales, 
1990-1999. Source: routine laboratory reports to Public Health 
Laboratory Service/Communicable Disease Surveillance Centre. 
indicate more difficult infections, which are not improv- 
ing after treatment with the first-line antimicrobial agent. 
Consequently, cultured organisms may not reflect more 
prevalent susceptible infections, which responded to the 
initial empiric treatment without specimens being taken. 
Once a specimen arrives in a microbiology labora- 
tory, other variations in practice occur: laboratories vary 
in how they handle the specimen for the isolation, 
identification and susceptibility testing of organisms 
found. There may be lack of speciation of some organ- 
isms, particularly those from urinary tract infections, 
where different species with differing inherent anti- 
microbial susceptibilities are often lumped together as 
‘coliforms’. Also, the definition of resistance (where 
breakpoints are set) is arbitrary. This is more conserva- 
tive in some countries than others and makes the 
comparison of antimicrobial resistance patterns across 
international borders difficult. Finally, once an organism 
has been isolated and identified, variations in practice 
can occur at the final step: that of laboratory reporting 
for surveillance purposes. Laboratories vary in terms of 
whether they report or not. Furthermore, even for 
laboratories that do report routinely, behaviour may not 
be consistent within or between laboratories. Labora- 
tories vary in their definition of clinically significant 
isolates and in the completeness of reporting. Thus all 
significant isolates may not be reported and the 
information on antimicrobial susceptibilities may be 
incomplete in those that are reported. 
BACTERAEMIA SURVEILLANCE 
Given these biases in the data, this paper focuses on the 
more prevalent pathogens causing bacteraemias in 
England and Wales. Bacteraemias tend to provide more 
robust data, as they indicate serious, potentially life- 
threatening infections, where the diagnosis of infection 
is usually more clear-cut than in other infections. Much 
of this data comes from voluntary reporting of clinically 
significant isolates by microbiologists in England and 
Wales to the PHLS Communicable Disease Surveillance 
Centre. There is good coverage across England and 
Wales, 91% of 229 laboratories identified in 1998 report- 
ing bacteraemias through this system.l 
Examining bacteraemia reports for the period 
1990-98, there was a 61% increase in these reports over 
the period, from 31,763 in 1990 to 51,232 in 1998.l This 
increased further to 55,917 in 2000 (reports to PHLS/ 
CDSC). There was a year-on-year proportional increase 
for most of the main pathogens, with the exception of 
Haemophilus influenzae, which declined steeply from 
1992 as a result of the vaccination programme. There 
was a steeper increase in the number of reports from 
1996, possibly reflecting improved laboratory reporting 
following the appointment of regional epidemiologists 
nationwide. Escherichia coli, Staphylococcus aureus, 
coagulase-negative staphylococci, pneumococci and 
either enterococci or klebsiellae accounted for 60% of 
reports each year. However, the amount of information 
on the susceptibility of these organisms has not been 
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Figure 2. Ciprofloxacin resistance in fscherichia co/i from blood and cerebrospinal fluid samples in England and Wales, 1990-1999. 
Source: routine laboratory reports to Public Health Laboratory Service/Communicable Disease Surveillance Centre. 
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keeping pace with the increased reporting, other than 
for methicillin in S. uureus.3 
Escherichia coli bacteraemia surveillance: 
antimicrobial resistance 
Focusing on susceptibility reporting in Escherichia coli 
bacteraemias, the commonest bacteraemias in the 
period 1990-99, ampicillin resistance has remained at a 
high level, approximately 55 % of cases, over the period 
(Figure 1). Gentamicin resistance increased from 1.7% 
in 1990 to 3% in 2000 and ciprofloxacin resistance 
has been increasing from extremely low levels at the 
beginning of the period less than l%, to 5% in 2000 
(Figure 2). 1,4 Comparisons with resistance rates in 
isolates referred to the Laboratory of Enteric Pathogens 
(LEP) at the Central Public Health Laboratory for 
further investigations5 showed that there was general 
agreement between the two datasets, indicating that the 
routine data reported to CDSC are sufficiently robust 
to be related to prescribing and population data. The 
proportions of resistant isolates in the two datasets were 
broadly similar. Resistance to ampicillin and trimetho- 
prim was frequent, while that to gentamicin and cipro- 
floxacin was rare, although gradually increasing. How- 
ever, the estimated proportional annual increase in 
resistance was most marked for gentamicin and 
ciprofloxacin. Differences between the datasets, such as 
lower rates of gentamicin resistance in the LEP dataset 
and of ciprofloxacin resistance in the CDSC one, may 
have arisen as a result of biases in the samples; for 
instance, only a small proportion of isolates from E. coli 
bacteraemias are referred to LEP for further investi- 
gations, while routine laboratory reports to CDSC may 
not contain full susceptibility information. In addition, 
some teaching hospitals were not reporting early in the 
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period and will have been under-represented. Variations 
in the definition of resistance or the use of non- 
standardized methodology could have also had an 
effect, distorting gentamicin and ciprofloxacin 
susceptibility reporting. 
Staphylococcus aureus bacteraemia surveillance: 
methicillin resistance 
Staphylococcus aureus is the second commonest 
reported bacteraemia. Resistance to methicillin, which 
indicates flucloxacillin resistance, has been growing 
dramatically since the early 1990s. This has resulted in a 
Governmental requirement for compulsory bacteraemia 
reporting from all acute National Health Service (NHS) 
Trusts in England from April 2001, with publication of 
the data by named Trusts in 2002-a departure for 
monitoring of hospital-acquired infections in this 
country.6 Methicillin resistance in reported S. aureus 
bacteraemias rose from 1.7 to 3.8% between 1990 and 
1993, then increased steeply to 32% in 1997 and 42% in 
2000 (Figure 3). 1,7 The steeper rise in the middle of the 
decade may have been, in part, related to improved 
laboratory reporting. This has also been seen in terms of 
improvements in reporting methicillin susceptibility, 
where there has been a decrease in the number of 
reports lacking this information.3 
Streptococcus pneumoniae bacteraemia surveillance: 
penicillin and erythromycin resistance 
In the case of another common pathogen in bacteraemias, 
Streptococcus pneumoniue, penicillin resistance has 
been gradually increasing from less than 1% in 1990 and 
1991 to 3.6% in 1998.l The picture for invasive pneumo- 
coccal isolates in 1999 showed significant regional 
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Figure 3. Staphylococcus aureus bacteraemia reports and methicillin susceptibility in England and Wales, 1991-2000. Source: 
routine laboratory reports to Public Health Laboratory Service/Communicable Disease Surveillance Centre. 
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variation in penicillin resistance rates, from a low of 
3% in the South West of England to a high of 11% in 
London.8 Erythromycin resistance is reported more 
commonly, increasing from 5% in 1990 to about 11% in 
the mid-1990s. In 1999, reported erythromycin-resist- 
ante rates in invasive isolates ranged from 10% to 16%.8 
Putting this in an international context, antimicrobial 
resistance in ,Y. pneumoniue is a bigger problem in many 
other countries;9 the United States’ Department of 
Health & Human Services Public Health Action Plan to 
Combat Antimicrobial Resistance states that in some 
areas of the USA up to 30% of pneumococci are no 
longer penicillin susceptible and that multidrug resist- 
ance is common.10 
Enterococcal bacteraemia surveillance: antimicrobial 
resistance 
The situation with enterococci differs in that there is 
a growing threat of vancomycin resistance. This is 
probably mainly a problem in Enterococcus faecium, 
where vancomycin resistance was reported in 24% of 
reports in 1998, compared to 5% of E. faecalis reports, 
reaching 27% and ll%, respectively, in 2000 (Figure 
4).l,ii However, significant numbers of laboratory 
reports of ampicillin resistance in E. fuecdis and the 
converse in E. fuecium are suggestive of frequent mis- 
speciation in the laboratory, as results from a sentinel 
survey suggest that most E. faecium spp. are amoxycillinl 
ampicillin resistant and that over 99% of E. fuecalis spp. 
are still susceptible. 
INFORMATION ON ANTIMICROBIAL 
PRESCRIPTIONS 
It is easier to collect, analyse and interpret antimicrobial 
resistance information from laboratory isolates than it is 
to examine prescribing data. This hinders efforts to 
establish the link between prescribing behaviour and 
antimicrobial resistance. Prescribing data are collected 
nationally by the Prescription Pricing Authority from 
prescriptions in general practice, and contain useful 
comparative information, but have limitations constrain- 
ing their use. l2 These limitations range from restrictions 
on what information is available and how widely it can 
be used (for instance, at regional level and above, data 
are normally only available by health authority rather 
than by individual general practitioner or practice); to 
weightings, which might not be appropriate for anti- 
microbials as they were developed for other agents (for 
instance, weightings according to age); to lack of 
information on the reason for the prescription. The 
latter, plus the inability to analyse the actual dose, 
frequency and duration of the prescribed antimicrobial, 
make it impossible to assess the suitability of the 
prescription. In addition, information is not available on 
prescriptions that were not ‘cashed in’ or prescriptions 
in private practice. These are substantial obstacles to 
linking antimicrobial resistance to prescribing behaviour, 
but there are even more insurmountable ones in 
hospital practice, where prescribing data is not yet 
collected routinely at district, regional or national level. 
LINKING ANTIMICROBIAL PRESCRIBING TO 
ANTIMICROBIAL RESISTANCE 
To date, much of the emphasis on altering prescribing 
behaviour has been targeted at general practitioner 
level through national campaignsI but it could be 
argued that this emphasis is misplaced as the infections 
seen and treated by general practitioners over the last 30 
years or more have not changed significantly and neither 
have the commonly used antimicrobial agents.i4 The 
changes in antimicrobial susceptibility of pathogens 
normally treated in the community in England and 
Wales have been small compared to the changes in 
susceptibility to the parenteral penicillins and cephalo- 
sporins, beta-lactamase inhibitors, newer beta-lactams, 
such as imipenem, aminoglycosides and glycopeptides- 
antimicrobials not normally prescribed in the com- 
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Figure 4. Vancomycin resistance in enterococci from blood and cerebrospinal fluid in England and Wales, 1990-2000. Source: 
routine laboratory reports to Public Health Laboratory Service/Communicable Disease Surveillance Centre. 
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munity. So maybe it is time to focus on antimicrobial 
prescribing in hospital practice. 
Studies examining prescribing practice have often 
unearthed interesting prescribing trends, but it is usually 
difficult to correlate these with antimicrobial resistance 
patterns, possibly for the reasons outlined above.Thus a 
study comparing Escherichia coli ampicillin and trime- 
thoprim resistance patterns by region with prescribing 
data15 found that some regions had consistently lower 
resistance rates, whereas others had consistently higher 
ones. Although there was a trend for regions with high 
total prescribing to have higher rates of ampicillin resist- 
ance, and one region stood out for having both low 
antimicrobial resistance rates and low prescribing, corre- 
lations between resistance patterns and prescribing 
were weak. Analysis of antimicrobial prescribing data by 
health authority in LondonI indicated district to district 
variation in prescribing practice within a small geo- 
graphical region and a notable decrease in antimicrobial 
prescribing between 1997/98 and 1998/99. This decrease 
in antibacterial prescribing by general practitioners, 
possibly allied to the national campaign, has also been 
seen on a wider scale, falling by 19% in England between 
the year ending September 1997 and that ending in 
September 1999.17 
THE FUTURE: A WAY FORWARD? 
It is clear from the data presented above that, although 
England and Wales are fortunate in having relatively 
low resistance rates to many antimicrobial agents 
compared to the experience in other parts of the world, 
there is a need to improve antimicrobial prescribing 
surveillance data, particularly in hospital practice. This is 
important for the investigation of the relationship 
between prescribing and resistance, but also to address 
the appropriateness of antimicrobial prescribing in com- 
munity and hospital practice. This is necessary to 
preserve the current enviable situation with regard to 
susceptibility to many important antimicrobial agents 
through their prudent use. The continuing rise in the 
incidence of methicillin-resistant Staphylococcus aureus 
is a notable exception to this situation, but probably 
reflects control of infection difficulties rather than un- 
satisfactory antimicrobial prescribing. 
Improving the quality of the data 
Ideally this surveillance of prescribing should be 
complemented by enhanced clinical observation in 
certain sentinel general practices and microbiology 
laboratories, geographically distributed so as to be 
representative of the general population. These practices 
would gather more detailed clinical information on 
patients presenting with infections and undertake 
appropriate microbiological investigations, according to 
agreed protocols, to reduce the inherent biases in 
routine surveillance data. 
Apart from the above-mentioned developments to 
improve information on antimicrobial prescribing, 
surveillance developments are required in terms of the 
quality of the data, the necessary supporting information 
technology, microbiological diagnostic and typing 
techniques and wider links to veterinary and agricultural 
practice. Improvements in the quality of the data require 
contributors to surveillance systems to be using the 
same language, so that the data are comparable. This 
means agreeing some basic definitions, such as definitions 
of infection and resistance, categorization of procedures, 
as well as categorization of health service facilities and 
units. This would allow comparisons by case mix, risk 
stratification and the use of appropriate denominators 
for health service activity. 
Improvements in the quality of the data also require 
underpinning modern information technology. This 
means installing systems that can automatically export 
data electronically and that are linked up so that 
patient-based data in one area, say the microbiology 
laboratory, can be associated with that from other areas, 
such as the wards, surgical theatres and pharmacy. 
Ideally unit-based data should also be linked up with 
data from the human resources department, so that 
levels of trained to untrained staff in high risk units, 
such as intensive care units, could be compared when 
estimating risk factors for spread of infections in 
hospitals. These information technology systems should 
also be able to indicate anomalous results, for instance 
penicillin resistance in Group A streptococci, so that the 
results can be checked for errors and true unusual 
isolates referred for further investigation. 
Improving laboratory methods 
In terms of laboratory methods, there is a need for 
improved speciation of organisms and more quantitative 
methods of susceptibility testing to ensure early recog- 
nition of ‘creeping’ resistance in a particular species. It 
is also important that there is a transition from 
surveillance of phenotypic characteristics to genotypic 
ones and consideration of the mechanisms of resistance 
rather than merely their expression. 
Links with veterinary and horticultural spheres 
Lastly, there is a need to forge surveillance links to the 
veterinary and horticultural spheres to identify the 
relationships between antibiotic use and resistance in 
farm animals and horticulture with antimicrobial 
resistance in humans. This surveillance would also be 
important in terms of tracking human illness associated 
with food back to the originating farm. 
Recent initiatives 
Is this a tall order? Perhaps, but the impact of 
accreditation and increasing automation of laboratories 
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as well as participation in national quality and controls 
assurance schemes push developments in this direction 
in England and Wales. The control of antimicrobial 
resistance, often allied to the control of hospital- 
acquired infection, has been increasing in priority over 
the past few years, following various reports,ls21 which 
culminated in the NHS Executive’s Health Service 
Circular in 1999 on Resistance to antibiotics and other 
antimicrobial agents,22 and the National Audit Office 
report on infection control in acute Trusts.23-25 Sub- 
sequent Government initiatives in terms of compulsory 
methicillin-resistant Staphylococcus aureus bacteraemia 
surveillance,z6 and inspections by the Commission for 
Health Improvement are also likely to impact on the 
technology required to undertake surveillance and 
ensure that infection control has a higher profile in 
hospital practice. These initiatives build on the pre- 
existing broad base of voluntary microbiology labora- 
tory and infection control team participation in surveil- 
lance schemes in these countries. 
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